{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:48:43Z","timestamp":1774439323784,"version":"3.50.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0131192","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T18:11:40Z","timestamp":1435169500000},"page":"e0131192","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats"],"prefix":"10.1371","volume":"10","author":[{"given":"Josephine T.","family":"Tauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold G.","family":"Erben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation","volume":"2010","author":"M Suttorp","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11899-012-0113-6","article-title":"Management of chronic myeloid leukemia in childhood","volume":"7","author":"M Suttorp","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"MI Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"E Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1210\/jc.2012-2426","article-title":"Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects","volume":"98","author":"K Vandyke","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"H Shima","year":"2011","journal-title":"J Pediatr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy","volume":"56","author":"SL Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"D Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"MV Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00223-010-9429-1","article-title":"Imatinib mesylate does not increase bone volume in vivo","volume":"88","author":"S O'Sullivan","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2009.150","article-title":"Imatinib mesylate causes growth plate closure in vivo","volume":"23","author":"K Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"D Russo","year":"2013","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"F Giona","year":"2013","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jchromb.2003.10.025","article-title":"Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations","volume":"799","author":"E Schleyer","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/8756-3282(93)90081-K","article-title":"Basic biomechanical measurements of bone: a tutorial","volume":"14","author":"CH Turner","year":"1993","journal-title":"Bone"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3945\/jn.108.099077","article-title":"Long-term marginal zinc supply is not detrimental to the skeleton of aged female rats","volume":"139","author":"RG Erben","year":"2009","journal-title":"J Nutr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"ML Bouxsein","year":"2010","journal-title":"J Bone Miner Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/chromsci\/48.5.334","article-title":"Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study","volume":"48","author":"G Bende","year":"2010","journal-title":"J Chromatogr Sci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions","volume":"62","author":"N Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.taap.2011.04.019","article-title":"Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats","volume":"254","author":"M Nurmio","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":"Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion","volume":"44","author":"B Peng","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"ref23","first-page":"#887","article-title":"Physiologically-based Pharmakokinetic Modeling of a Protein-Tyrosine Kinase Inhibitor, STI571. 2nd AAPS Annual Meeting and Exposition","volume":"1","author":"C Tanaka","year":"1999","journal-title":"AAPS Journal"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1020884312053","article-title":"Food intake, water intake, and drinking spout side preference of 28 mouse strains","volume":"32","author":"AA Bachmanov","year":"2002","journal-title":"Behav Genet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/0192623310388431","article-title":"Gavage-related reflux in rats: identification, pathogenesis, and toxicological implications (review)","volume":"39","author":"S Damsch","year":"2011","journal-title":"Toxicol Pathol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"MA Champagne","year":"2004","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"B Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"S Picard","year":"2007","journal-title":"Blood"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"#522","DOI":"10.1182\/blood.V124.21.522.522","article-title":"Impairment of Longitudinal Growth by Tyrosine Kinase Inhibitor (TKI) Treatment\u2014Data from a Large Pediatric Cohort with Chronic Myeloid Leukemia (CML)","volume":"124","author":"JT Tauer","year":"2014","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"F Millot","year":"2014","journal-title":"Eur J Cancer"},{"key":"ref31","article-title":"Imatinib \/ Chemical Structure, Pharmacology and Adverse Effects","author":"K Vandyke","year":"2013"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"S Fitter","year":"2008","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.12373","article-title":"Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia","volume":"93","author":"S J\u00f6nsson","year":"2008","journal-title":"Haematologica"},{"issue":"21","key":"ref34","doi-asserted-by":"crossref","first-page":"#1472","DOI":"10.1182\/blood.V122.21.1472.1472","article-title":"Impact Of The Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib In Young Rats On The Vertebral Body","volume":"122","author":"JT Tauer","year":"2013","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","article-title":"Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib","volume":"94","author":"S O'Sullivan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00774-006-0684-1","article-title":"Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)","volume":"24","author":"W Ando","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"I El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"AL Dewar","year":"2006","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/cc.4.7.1788","article-title":"Inhibition of c-fms by imatinib: expanding the spectrum of treatment","volume":"4","author":"AL Dewar","year":"2005","journal-title":"Cell Cycle"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2403071","article-title":"Imatinib inhibits the in vitro development of the monocyte\/macrophage lineage from normal human bone marrow progenitors","volume":"17","author":"AL Dewar","year":"2003","journal-title":"Leukemia"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"S O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"BA Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response","volume":"82","author":"S Osorio","year":"2007","journal-title":"Am J Hematol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.23155","article-title":"Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib","volume":"87","author":"S J\u00f6nsson","year":"2012","journal-title":"Am J Hematol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"A Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"K Vandyke","year":"2010","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0033-1343483","article-title":"TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model","volume":"225","author":"A Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1209007","article-title":"FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance","volume":"25","author":"JR Taylor","year":"2006","journal-title":"Oncogene"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0131192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T02:36:35Z","timestamp":1599186995000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0131192"}},"subtitle":[],"editor":[{"given":"Connie J","family":"Eaves","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0131192","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]}}}